# Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

> **NCT02279745** · PHASE2 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Ralinepag

## Key facts

- **NCT ID:** NCT02279745
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-08
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279745, "Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02279745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*